Furthermore, mononuclear phagocytes are the primary mediators of ADCP and so their elimination at tumor sites does not make anti-CSF-1R mAb blockade an attractive strategy to combine with established direct targeting mAbs. The gene discussed is CSF1R; the disease is neoplasm.